BMRN vs. ICLR: BioMarin Pharmaceutical vs. ICON Stock Comparison

November 11, 2026

How do BioMarin Pharmaceutical (BMRN) and ICON (ICLR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BioMarin Pharmaceutical (BMRN) and ICON (ICLR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BMRN is classified in Biotechnology while ICLR is classified in Life Sciences Tools & Services.

Company profile comparison for BioMarin Pharmaceutical (BMRN) and ICON (ICLR)
Profile Item	BMRN	ICLR
Name	BioMarin Pharmaceutical Inc.	ICON plc
Country/Region	United States	Ireland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	10.85 billion USD	15.34 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	July 26, 1999	May 15, 1998
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

BMRN

ICLR

GSPC

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for BioMarin Pharmaceutical (BMRN) and ICON (ICLR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for BioMarin Pharmaceutical (BMRN) and ICON (ICLR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BioMarin Pharmaceutical (BMRN) and ICON (ICLR)
Metric	BMRN	ICLR
Total Return (1Y)	8.82%	30.55%
Total Return (3Y, Annualized)	-12.54%	-6.05%
Total Return (5Y, Annualized)	-7.51%	-5.40%

Risk Profile

Drawdown History

BMRN

ICLR

GSPC

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for BioMarin Pharmaceutical (BMRN) and ICON (ICLR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BioMarin Pharmaceutical (BMRN) and ICON (ICLR)
Metric	BMRN	ICLR
Volatility (1Y, Annualized)	35.50%	68.62%
Beta (5Y)	0.24	1.17
Max Drawdown (5Y)	-57.64%	-76.87%
Avg. Volume (3M)	2.28M	943.50K

Risk-Adjusted Performance

Risk-Return Positioning

BMRN and ICLR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BioMarin Pharmaceutical (BMRN) and ICON (ICLR)
Metric	BMRN	ICLR
Sharpe Ratio (1Y)	0.13	0.38
Sortino Ratio (1Y)	0.23	0.52

Profitability

ROE (TTM)

BioMarin Pharmaceutical (BMRN) reports a negative ROE of -0.31%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile ICON (ICLR) reports 4.70%, ranking against industry peers normally.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.31%

Max: 109.18%
Q3: 6.23%
BMRN: -0.31%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70%

Max: 109.18%
Q3: 6.23%
ICLR: 4.70%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

BioMarin Pharmaceutical (BMRN) reports a negative net margin of -0.52%, usually indicating a net loss over the period. Meanwhile ICON (ICLR) reports 5.26%, ranking against industry peers normally.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

-0.52%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
BMRN: -0.52%
Q1: -4.14%
Min: -17.05%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.26%

Max: 18.05%
ICLR: 5.26%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BioMarin Pharmaceutical (BMRN) at 26.58% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.58%

Max: 83.12%
BMRN: 26.58%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.73%

Max: 83.12%
Q3: 14.77%
ICLR: 10.73%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BioMarin Pharmaceutical (BMRN) and ICON (ICLR)
Metric	BMRN	ICLR
ROE (TTM)	-0.31%	4.70%
ROA (TTM)	3.89%	0.85%
Net Margin (TTM)	-0.52%	5.26%
Operating Margin (TTM)	26.58%	10.73%
Gross Margin (TTM)	53.21%	23.44%

Growth

Revenue Growth

Both BioMarin Pharmaceutical (BMRN) at 12.87% and ICON (ICLR) at 0.76% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): A comparison of their Revenue Growth across different time periods.

EPS Growth

BioMarin Pharmaceutical (BMRN) at -18.55% is around its peer norm for EPS growth, while ICON (ICLR) at -71.56% drops into the bottom quartile, signaling weaker earnings momentum.

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for BioMarin Pharmaceutical (BMRN) and ICON (ICLR)
Metric	BMRN	ICLR
Revenue Growth (YoY)	12.87%	0.76%
Revenue Growth (3Y CAGR)	15.40%	2.15%
EPS Growth (YoY)	-18.55%	-71.56%
EPS Growth (3Y CAGR)	33.89%	-23.82%

Financial Strength

Current Ratio (MRQ)

Both BioMarin Pharmaceutical (BMRN) at 2.44 and ICON (ICLR) at 1.32 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.44

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
BMRN: 2.44
Min: 0.10

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.32

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ICLR: 1.32
Min: 0.10

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

ICON (ICLR) at 0.38 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.67

Max: 1.42
BMRN: 0.67
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max: 1.42
Q3: 0.65
ICLR: 0.38
Median: 0.15
Q1: 0.02
Min: 0.00

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BioMarin Pharmaceutical (BMRN) and ICON (ICLR)
Metric	BMRN	ICLR
Current Ratio (MRQ)	2.44	1.32
Debt / Equity (MRQ)	0.67	0.38
Net Debt / EBITDA	4.04	5.55

Dividends

Dividend Yield (TTM)

Neither BioMarin Pharmaceutical (BMRN) nor ICON (ICLR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BMRN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BioMarin Pharmaceutical (BMRN) nor ICON (ICLR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BMRN: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BioMarin Pharmaceutical (BMRN) and ICON (ICLR)
Metric	BMRN	ICLR
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: ICON (ICLR) trades at 81.90 times trailing earnings, ranked against its peers, while BioMarin Pharmaceutical (BMRN) has no P/E ratio this period.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
BMRN: --

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.90

Max: 85.34
ICLR: 81.90
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): BMRN does not report P/E ratio, so it has no value marker; ICLR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Both BioMarin Pharmaceutical (BMRN) at 2.97 and ICON (ICLR) at 1.86 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.97

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
BMRN: 2.97
Min: 0.01

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.86

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
ICLR: 1.86
Min: 0.01

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile against book while BioMarin Pharmaceutical (BMRN) at 1.73 is valued near its industry’s middle — ICLR is cheaper on assets, though weigh it against ROE and asset quality.

BMRN

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.73

Max: 13.53
Q3: 6.54
Median: 3.25
BMRN: 1.73
Q1: 1.69
Min: -5.59

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.68

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
ICLR: 1.68
Min: -5.59

BioMarin Pharmaceutical (BMRN) vs. ICON (ICLR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BioMarin Pharmaceutical (BMRN) and ICON (ICLR)
Metric	BMRN	ICLR
P/E Ratio (TTM)	--	81.90
P/S Ratio (TTM)	2.97	1.86
P/B Ratio (MRQ)	1.73	1.68
Free Cash Flow Yield (TTM)	-0.15%	3.51%